During Monday’s Current trade, Shares of Christopher & Banks Corporation (NYSE:CBK), lost -0.70% to $1.42.
Christopher & Banks Corporation (CBK) stated results for the thirteen week period ended May 2, 2015.
Results for the Thirteen Week Period Ended May 2, 2015
- Net sales totaled $91.6 million, as contrast to $103.4 million for the thirteen weeks ended May 3, 2014. During the quarter, the Company operated an average of 6.0% fewer stores than during the comparable period last year, reflecting its MPW store conversion program.
- Same-store sales reduced 11.7% in the thirteen weeks ended May 2, 2015, as contrast to the thirteen weeks ended May 3, 2014; this follows a 0.2% same-store sales decrease in last year’s first quarter.
- Gross margin was 35.2% contrast to 36.7% in the first quarter of fiscal 2014.
- Operating loss was $2.5 million for the thirteen week period ended May 2, 2015. This compares to operating income of $2.8 million in the first quarter of fiscal 2014.
Christopher & Banks Corporation, through its auxiliaries, operates as a retailer of women’s apparel and accessories in the United States. The company designs, sources, and sells women’s apparel and accessories to customers ranging in age from 45 to 60. Its stores offer women’s apparel comprising of knit tops, woven tops, jackets, sweaters, skirts, denim bottoms, bottoms made of other fabrics, leisure wear, and dresses in missy, petite, and women sizes, in addition to jewelry and accessories.
Shares of Fairchild Semiconductor Intl Inc (NASDAQ:FCS), declined -1.11% to $13.77, during its current trading session.
Fibrocell Science, Inc.,, an autologous cell and gene therapy company focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs, declared that David Pernock, Chairman and Chief Executive Officer, will present at the Ladenburg Thalmann 2015 Healthcare Conference at 1:00 pm EDT on Tuesday, September 29 in New York City. ‘
Fibrocell Science, Inc., an autologous cell therapy company, focuses on developing treatments for skin and connective tissue diseases with unmet medical needs. The company, through its proprietary autologous fibroblast technology, develops azficel-T, which is in Phase II clinical trials for the treatment of vocal cord scarring and restrictive burn scarring.
Koninklijke Philips NV (ADR) (NYSE:PHG), during its Monday’s current trading session decreased -0.89% to $25.63.
Royal Philips (NYSE: PHG) launched the 3rd Annual “ISRRT Dosewise Radiographer of the Year” contest to further enhance awareness about the risks of radiation dose exposure during diagnostic image testing. The annual contest, conducted in partnership with the International Society of Radiographers and Radiological Technologists (ISRRT), recognizes dose-conscious radiographers from around the world for their contribution in improving dose tracking and measurement and efforts toward overall radiation dose reduction.
As one of the early pioneers of radiation dose administration solutions, Philips extended its leadership with the launch of the DoseWise Portal, a comprehensive radiation dose administration software solution that monitors dose exposure risk for patients and clinicians. It allows providers to proactively record, analyze and monitor imaging radiation dose for patients and clinicians across multiple diagnostic settings. The solution automates monitoring and tracking, facilitating compliance with reform and accreditation requirements. The “ISRRT Dosewise Radiographer of the Year” contest is geared to encourage innovation and generate new ways to manage radiation dose risk.
Koninklijke Philips N.V. engages in healthcare, consumer lifestyle, and lighting businesses worldwide. It provides various integrated clinical solutions, counting radiation oncology and portfolio administration; computed tomography, magnetic resonance imaging, and molecular imaging products; digital X-ray and mammography products; interventional X-ray products in cardiology, radiology, surgery, and other areas; and ultrasound products.
Finally, Horizon Pharma PLC (NASDAQ:HZNP), gained 0.55%, to $29.15.
Horizon Pharma plc (NASDAQ: HZNP), a biopharmaceutical company focused on improving patients’ lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, recently declared it received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for U.S. patent application number 14/705,606 (U.S. publication number 2015-0231262), entitled “Diclofenac Topical Formulation” that covers Horizon’s U.S. approved product PENNSAID® (diclofenac sodium topical solution) 2% w/w (PENNSAID 2%).
This Notice of Allowance concludes the substantive examination of the patent application and will result in the issuance of a U.S. patent after administrative processes are accomplished. The U.S. patent planned to issue from this application will expire October 17, 2027. After issuance, Horizon plans to list the patent in the FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations, or Orange Book.
Horizon Pharma plc, a specialty biopharmaceutical company, engages in identifying, developing, acquiring or in-licensing, and commercializing medicines for the treatment of arthritis, pain, inflammatory, and/or orphan diseases in the United States and internationally. The company offers ACTIMMUNE for reducing the frequency and severity of serious infections associated with chronic granulomatous disease; DUEXIS, a proprietary tablet formulation for the relief of signs and symptoms of rheumatoid arthritis (RA) and osteoarthritis (OA), and to decrease the risk of developing upper gastrointestinal ulcers in patients who are taking ibuprofen for these indications; PENNSAID for the treatment of pain of OA of the knee; and VIMOVO, a proprietary fixed-dose multi-layer delayed-release tablet for the relief of the signs and symptoms of OA, RA, and ankylosing spondylitis (AS).
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
